TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03672708

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cresyl violet
Description: cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
Study: NCT01259414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solvent with specific gravity less than lipiodol
Description: TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solvent with specific gravity equivalent to lipiodol
Description: TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
Study: NCT00093626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study: NCT02547818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALZT-OP1a
Description: 1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALZT-OP1a
Description: 1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALZT-OP1b
Description: Anti-inflammatory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALZT-OP1b
Description: Anti-inflammatory

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ALZT-OP1a
Description: Non-active capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ALZT-OP1a
Description: Non-active capsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ALZT-OP1b
Description: Non-active tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ALZT-OP1b
Description: Non-active tablets
Study: NCT01440894

Intervention type: DEVICE
Intervention: Comparison test
Description: Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D.
Study: NCT02551887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated Reminder
Description: Automated reminder shown to provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Reminder Plus Script
Description: Provider sees both reminder and script.
Study: NCT02004093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2 IV every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 IV every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
Study: NCT01909427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
Study: NCT03613662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-102
Description: Injection
Study: NCT00115791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSD1235
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study: NCT02303704

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multiport antegrade cardioplegia
Description: Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic root antegrade cardioplegia
Description: only cold blood cardioplegia was used for myocardial protection without hotshot.
Study: NCT03410836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous lidocaine (IVL)
Description: lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
Study: NCT02543827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV140
Description: The subjects will receive daily dose of MV140 during 3 or 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV140
Description: The subjects will receive daily dose of MV140 during 3 or 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The subjects will receive daily dose of placebo during 3 or 6 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive daily dose of placebo during 3 or 6 months
Study: NCT04733339

Intervention type: BEHAVIORAL
Intervention: Secondary Prevention
Description: behavioral changes in dieting and exercising up to one year after clinical discharge

Intervention type: BEHAVIORAL
Intervention: Secondary Prevention
Description: behavioral changes in dieting and exercising up to one year after clinical discharge
Study: NCT04032730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wisepill device
Description: Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis.
Study: NCT01528813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG laser + amorolfine lacquer
Description: To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amorolfine lacquer
Description: To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
Study: NCT06211465

Intervention type: PROCEDURE
Intervention: Total joint arthroplasty
Description: Hip or knee total joint arthroplasty
Study: NCT01515293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Appendectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional appendectomy
Study: NCT01400581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Intervention
Description: See description of Intervention arm
Study: NCT02871804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined resection of the splenic vein
Description: combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: separated resection of the splenic vein
Description: separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
Study: NCT00518388

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Focus groups each lasting about 2 hours.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
Study: NCT01542268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline
Description: Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pentoxifylline placebo
Description: Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
Study: NCT03765242

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT04426604

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Light induced fluorescence intraoral camera
Description: Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence device
Description: Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
Study: NCT02004093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
Study: NCT04426604

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual-tactile assessment method according to FDI criteria
Description: Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations
Study: NCT01881893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHD-CARE Program
Description: The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
Study: NCT03139825

Intervention type: OTHER
Group type: OTHER
Intervention: Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)
Description: Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
Study: NCT02946593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroll Safe outdoor fall prevention program
Description: The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 \& 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
Study: NCT02004093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
Study: NCT04346381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Intravenous (IV) camrelizumab on Day 1 of each cycle
Study: NCT02946593

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outdoor fall prevention brochure
Description: The control group participants will be given a written brochure on tips for preventing outdoor falls.
Study: NCT04346381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: famitinib po qd
Study: NCT00414596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRX9000™
Description: Device is designed to apply spinal decompressive forces.
Study: NCT04030871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule Dome G-Tube
Description: Feeding replacement tubes with two different FDA approved devices in forty subjects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Bolus feeding tube
Description: Feeding replacement tubes with two different FDA approved devices in forty subjects
Study: NCT00757302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLN procedure (CarolIReS camera)
Description: Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLN procedure (CarolIReS camera)
Description: Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).
Study: NCT05354076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride liposome injection
Description: According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
Study: NCT02205411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartAssist 5® VAD System
Description: The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control VAD
Description: The HeartMate II® VAD or HVAD®
Study: NCT01846624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study: NCT05522816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 0.01% (0.1 mg/g)
Description: Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 0.1% (1.0 mg/g)
Description: Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 1% (10 mg/g) for 5 days
Description: Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Description: Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
Study: NCT00895141

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated Fat Diet
Description: Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated Fat Diet
Description: Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
Study: NCT03976791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enlarged internal incision
Description: enlarging the internal incision about 0.4mm

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: regular 2.2mm incision
Description: 2.2mm microincision coaxial phacoemulsification
Study: NCT03687814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet/PEG 3350
Description: Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham diet/PEG 3350
Description: Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
Study: NCT04009317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: a multi-target protein kinase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: a multi-target protein kinase inhibitor.
Study: NCT02022345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Study: NCT00606606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Study: NCT02722993

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03743181

Intervention type: OTHER
Intervention: pharmaceutical care services
Description: detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
Study: NCT02986360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vidscrip educational video
Description: Vidscrip educational video provide to women
Study: NCT05035381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
Description: MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
Study: NCT02900378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 (Sacubitril/Valsartan)
Description: LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696 (Sacubitril/Valsartan)
Description: Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Study: NCT03571529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-driven exoskeleton hand robot
Description: Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale